trending Market Intelligence /marketintelligence/en/news-insights/trending/sIq0XvvLGwdDmkDCbdd-0A2 content esgSubNav
In This List

Alterity drug wins EU orphan-drug tag for Parkinson's-like disorder

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Alterity drug wins EU orphan-drug tag for Parkinson's-like disorder

Alterity Therapeutics Ltd. said the European Commission granted an orphan-drug designation to PBT434 for treating a neurodegenerative disorder called multiple system atrophy.

Multiple system atrophy, or MSA, is a rare, degenerative neurological disorder that affects the body's involuntary functions, including blood pressure, breathing, bladder function and muscle control. It is a form of atypical Parkinson's, where patients present symptoms similar to Parkinson's but do not respond to therapy.

Under the designation, the Australian biotechnology company will have market exclusivity in the EU for 10 years, subject to regulatory approval. Additionally, Alterity will be eligible for benefits such as assistance in developing clinical trials, reduced fees and access to research grants.

The European Medicines Agency's Committee for Orphan Medicinal Products recommended PBT434 for the designation in November 2019.

The U.S. Food and Drug Administration granted orphan-drug designation to PBT434 to treat MSA.